Latest kidney cancer Stories
Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer.
Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.In one of the first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for kidney cancer more effective and better tolerated....
Antigenics Inc. (NASDAQ: AGEN) reported results for the quarter ended September 30, 2008.
U.S. researchers found aggressive, personalized treatment increases kidney cancer patient survival compared to the one-size-fits-all traditionally used.
Antigenics, a biotechnology company, has submitted a marketing authorization application to the European Medicines Agency requesting approval for Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision.
Antigenics Inc. (NASDAQ: AGEN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting approval for Oncophage(R) in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision.
Antigenics Inc. (NASDAQ: AGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted the necessary permission to allow for the export of Oncophage (R) (vitespen) to Russia.
By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives.
Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib).
London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.